Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Sign Up

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Curevac N V Ord (0A9E) Share Price

There is currently no data for 0A9E.L

Buy/Sell	Volume	Trade Prc	Trade Type	Trade Time
Curevac N V Ord (0A9E) Latest Trades
Unknown*	400	$4.645	OTC Trade	17:26:23 - 05-Jan-26
Unknown*	400	$4.648	OTC Trade	17:26:23 - 05-Jan-26
Unknown*	1,024	$4.6493	OTC Trade	17:26:23 - 05-Jan-26
Unknown*	100	$4.64	OTC Trade	17:26:23 - 05-Jan-26
Unknown*	1,165	$4.6299	OTC Trade	17:16:51 - 05-Jan-26
Unknown*	400	$4.628	OTC Trade	17:16:51 - 05-Jan-26
Unknown*	2	$4.62	OTC Trade	16:56:00 - 05-Jan-26
Unknown*	3	$4.6014	Cross OTC Trade	16:06:36 - 05-Jan-26
Unknown*	44	$4.57	Cross OTC Trade	14:48:09 - 05-Jan-26
Unknown*	3	$4.57	Cross OTC Trade	14:40:45 - 05-Jan-26

See more Curevac N V Ord trades

Curevac N V Ord (0A9E) Share Price History
Time period: to
Date	Open	High	Low	Close	Volume
9th Jan 2026 (Fri)	5.134	5.134	5.134	5.134	0
8th Jan 2026 (Thu)	5.134	5.134	5.134	5.134	0
7th Jan 2026 (Wed)	5.134	5.134	5.134	5.134	0

See more Curevac N V Ord price history

Date	Source	Headline
Curevac N V Ord (0A9E) Regulatory News
28th May 2024 12:01 pm	EQS	CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
23rd May 2024 12:01 pm	EQS	CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
24th Apr 2024 12:08 pm	EQS	CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update
24th Apr 2024 12:04 pm	EQS	CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
24th Apr 2024 12:01 pm	EQS	CureVac Appoints Thaminda Ramanayake as New Chief Business Officer
18th Apr 2024 12:01 pm	EQS	CureVac to Report Fourth Quarter and Full-Year 2023 Financial Results and Business Update on April 24, 2024
16th Apr 2024 12:02 pm	EQS	CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines
4th Apr 2024 12:02 pm	EQS	CureVac Announces Promising Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSK
5th Jan 2024 12:02 pm	EQS	CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
19th Dec 2023 2:24 pm	EQS	CureVac Announces Decision of German Federal Patent Court in Broad Patent Litigation with BioNTech SE

See more Curevac N V Ord regulatory news

FTSE 100 Latest

Value10,369.75

Change60.53